Lonza expands solid-form services at Oregon facility The company has increased capabilities at its Bend, Oregon location, including its SimpliFiH Solutions first-in-human services for small-molecule drugs.
Switzerland-based Lonza has increased its solid-form selection services offered at its Bend, Oregon site. The expansion is designed to help complement its SimpliFiH Solutions services, which include phase-appropriate drug substance, product development and manufacture.
Michael Grass, head of solid form services for Lonza pharma and Biotech Small Molecules, spoke with Outsourcing-Pharma about the reasons for the expansion and what they might mean for potential customers.
OSP: Could you please share an overview of your SimpliFiH solutions what offerings are under that umbrella?
Continuus lands $69.3m US drug manufacturing contract The small-molecule pharmaceuticals manufacturer secured a DoD/HHS government contract to manufacture critical medicines for a range of conditions.
Continuus Pharmaceuticals, a firm that uses proprietary integrated continuous manufacturing (ICM) technology to manufacture drugs, has been granted a $69.3m (57 EUR) contract to manufacture three different medicines. The contract, awarded by the US Department of Defense (DoD) and Department of Health and Human Services (HHS), also will be used for construction of the country’s first GMP-certified facility for ICM-driven facility of small-molecule marketed drugs, generic medicines and investigational therapies, through all clinical trial phases and the rest of a product’s lifecycle.
Sanofi unveils EUROAPI as name of new API company The global pharmaceutical firm expects big things from its newly formed active pharmaceutical ingredients company, to be led by new CEO Karl Rotthier.
Sanofi has unveiled EUROAPI as the name of its new European active pharmaceutical ingredients (API) company. Additionally, the firm has appointed Karl Rotthier as its future CEO.
According to Sanofi, the new company stands to be the largest API organization in the European Union, with projected sales of approximately €1b ($1.2b USD) by 2022. Additionally, the parent company anticipates EUROAPI will rank first on the continent in small-molecule APIs and second in the global API market.